A timeline of Parker Institute for Cancer Immunotherapy's milestones and achievements.

1. www.parkerici.org
Year In Review
The Parker Institute for Cancer Immunotherapy brings together the best scientists, clinicians
and industry partners to build a smarter and more coordinated cancer immunotherapy research
effort. Our goal is to accelerate the development of breakthrough immune therapies capable of
turning most cancers into curable diseases.
Since the launch, we have hit many significant milestones. Here’s a snapshot of our year:
April 13, 2016 The Parker Institute for Cancer Immunotherapy launches
June 1, 2016 The Parker Institute names first class of Parker Scholars and Fellows, a
program to support the most promising young researchers in
immunotherapy
June 16, 2016 National Institutes of Health committee greenlights the use of CRISPR in
human cancer immunotherapy trial funded in part by the Parker Institute
September 7, 2016 Parker Institute members are instrumental in the Cancer Moonshot Blue
Ribbon Panel’s recommendations to accelerate cancer research
October 5, 2016 The Parker Institute sponsors a workshop with Friends of Cancer
Research to discuss common issues in immunotherapy development with
the FDA
October 19, 2016 Sean Parker, founder, and James Allison, PhD, center director at MD
Anderson, talk about hacking cancer at the Vanity Fair New
Establishment Summit
October 25, 2016 The Parker Institute at the University of Pennsylvania officially launches
November 15, 2016 The Parker Institute and its six research centers streamline the review
process for faster approval of multi-center clinical trials
December 1, 2016 The Tumor Neoantigen Selection Alliance launches with more than 35
academic, nonprofit and industry participants
December 2016 Time Magazine names CRISPR scientists among runners-up for Person
of the Year – story features Sean Parker and Carl June, MD, center
director at the University of Pennsylvania
February 15, 2017 The Parker Institute is named one of top 10 most innovative biotech
companies by Fast Company
March 28, 2017 First major biopharma industry partnership with Bristol-Myers Squibb and
the Cancer Research Institute is announced
April 4, 2017 Announcement of pancreatic cancer clinical trial involving CD40
April 10, 2017 First major scientific paper published in Nature by Parker Institute
scientists at the University of Pennsylvania and Memorial Sloan Kettering

2. www.parkerici.org
Our Progress
A closer look at key achievements over the past year and what they mean for cancer research:
 The Parker Institute and its six research centers streamlined the review process for
faster approval of multi-center clinical trials through the adoption of an institutional
review board (IRB) reliance agreement. This approach is designed to get clinical trials off
the ground in weeks, rather than months, saving both time and resources.
 In December 2016, the Parker Institute and the Cancer Research Institute launched the
Tumor Neoantigen Selection Alliance to advance personalized cancer treatments through
neoantigen discovery. This global collaboration includes scientists from more than 35 of the
leading neoantigen research groups in academia, nonprofit and industry.
 The Parker Institute is partnering with Bristol-Myers Squibb and the Cancer Research
Institute to leverage efficiencies in cancer research and accelerate next-generation cancer
immunotherapy treatments. This is the Parker Institute’s first major agreement with a
biopharma partner.
 We are launching clinical trials and projects across our research centers, including:
o A trial led by Memorial Sloan Kettering Cancer Center focused on treating
melanoma. This is a collaboration with all six research centers, which will expedite
enrollment and leverage the collective expertise of our network of researchers.
o A study by The University of Texas MD Anderson Cancer Center that looks at the
connection between a person’s microbiome and immune system in melanoma
patients. This could have major implications for cancer prognosis and treatment. The
first clinical trial is expected to launch later this year.
 Parker Institute data scientists work closely with our network of researchers, which has
resulted in more than 20 one-on-one collaborations across our six research centers.
 Since April 2016, Parker Institute researchers have published more than 550 articles
across 205 journals, and 30 papers had authors from multiple institutions.
 To train the next generation of scientific leaders in cancer immunotherapy, we created the
Parker Scholars, the Parker Bridge Scholars and the Parker Fellows. These programs
help the most talented and ambitious young researchers advance in the field. We currently
have five scholars and fellows and will announce the 2017 Parker Institute young
researchers in the coming weeks.
Our Network: By the Numbers
6 Centers
300+ Nation’s
TopResearchers60+ Labs
40+ Industry and
NonprofitPartners 4 Clinical Trials
5 Fellows &
Scholars